SPRR2A and neoplasm: Hence, the joint use of CDDP and pIL-12 could eliminatetumor cells and adjust the tumor immune environment at the same time,potentially leading to improved chemoimmunotherapy.97 In a similar study, a new nanosystem based on PMet wasdeveloped to deliver both doxorubicin and pIL-12 for the combinedtreatment of metastatic breast cancer.